Change search
ReferencesLink to record
Permanent link

Direct link
HRAS mutation prevalence and associated expression patterns in pheochromocytoma
Karolinska Institute, Sweden; Karolinska University, Sweden.
Linköping University, Department of Clinical and Experimental Medicine, Division of Cell Biology. Linköping University, Faculty of Medicine and Health Sciences.
Linköping University, Department of Clinical and Experimental Medicine. Linköping University, Faculty of Medicine and Health Sciences.
University of Lorraine, France.
Show others and affiliations
2016 (English)In: Genes, Chromosomes and Cancer, ISSN 1045-2257, E-ISSN 1098-2264, Vol. 55, no 5, 452-459 p.Article in journal (Refereed) PublishedText
Abstract [en]

Pheochromocytomas (PCC) and abdominal paragangliomas (PGL) display a highly diverse genetic background and recent gene expression profiling studies have shown that PCC and PGL (together PPGL) alter either kinase signaling pathways or the pseudo-hypoxia response pathway dependent of the genetic composition. Recurrent mutations in the Harvey rat sarcoma viral oncogene homolog (HRAS) have recently been verified in sporadic PPGLs. In order to further establish the HRAS mutation frequency and to characterize the associated expression profiles of HRAS mutated tumors, 156 PPGLs for exon 2 and 3 hotspot mutations in the HRAS gene was screened, and compared with microarray-based gene expression profiles for 93 of the cases. The activating HRAS mutations G13R, Q61R, and Q61K were found in 10/142 PCC (7.0%) and a Q61L mutation was revealed in 1/14 PGL (7.1%). All HRAS mutated cases included in the mRNA expression profiling grouped in Cluster 2, and 21 transcripts were identified as altered when comparing the mutated tumors with 91 HRAS wild-type PPGL. Somatic HRAS mutations were not revealed in cases with known PPGL susceptibility gene mutations and all HRAS mutated cases were benign. The HRAS mutation prevalence of all PPGL published up to date is 5.2% (49/950), and 8.8% (48/548) among cases without a known PPGL susceptibility gene mutation. The findings support a role of HRAS mutations as a somatic driver event in benign PPGL without other known susceptibility gene mutations. HRAS mutated PPGL cluster together with NF1- and RET-mutated tumors associated with activation of kinase-signaling pathways.

Place, publisher, year, edition, pages
WILEY-BLACKWELL , 2016. Vol. 55, no 5, 452-459 p.
National Category
Clinical Medicine
URN: urn:nbn:se:liu:diva-127407DOI: 10.1002/gcc.22347ISI: 000372913800005PubMedID: 26773571OAI: diva2:925597

Funding Agencies|Swedish Cancer Foundation; StratCan; Swedish Research Council; Cancer Research Foundations of Radiumhemmet; Karolinska Institutet; Stockholm County Council

Available from: 2016-05-02 Created: 2016-04-26 Last updated: 2016-05-24

Open Access in DiVA

fulltext(277 kB)13 downloads
File information
File name FULLTEXT01.pdfFile size 277 kBChecksum SHA-512
Type fulltextMimetype application/pdf

Other links

Publisher's full textPubMed

Search in DiVA

By author/editor
Welander, JennyGustavsson, IdaSöderkvist, PeterGimm, Oliver
By organisation
Division of Cell BiologyFaculty of Medicine and Health SciencesDepartment of Clinical and Experimental MedicineDepartment of Clinical Pathology and Clinical GeneticsDivision of Clinical SciencesDepartment of Surgery in Linköping
In the same journal
Genes, Chromosomes and Cancer
Clinical Medicine

Search outside of DiVA

GoogleGoogle Scholar
Total: 13 downloads
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 112 hits
ReferencesLink to record
Permanent link

Direct link